Method for determining the effect of cell lysis of a sample on a test substance
By using tandem measurements of extracellular analytes and intracellular markers, the method corrects for cell lysis effects, ensuring accurate determination of extracellular analyte concentrations in blood samples.
Patent Information
- Application Number
- JP2024532855
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-03
- Filing Date
- 2022-12-02
- Publication Date
- 2024-11-26
AI Technical Summary
Current methods fail to accurately determine the true extracellular concentration of analytes in blood samples due to the influence of cell lysis, particularly hemolysis, leading to inaccurate measurement results.
A method involving tandem measurements of extracellular analytes and intracellular markers, such as cell-free hemoglobin, to establish a mathematical relationship that corrects for the effects of cell lysis, allowing for precise estimation of the true extracellular concentration by linear or non-linear regression.
Enables accurate determination of the true extracellular concentration of analytes by accounting for the contribution of cell lysis, providing reliable and precise measurement results.
Smart Images

Figure 2024543999000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of sample testing. More specifically, the present disclosure relates to the field of testing for analytes in the extracellular phase of a cell-containing sample, such as a blood sample. [Background technology]
[0002] Certain analytes of interest in blood samples (e.g., electrolytes and ions) are present in significantly different concentrations in the extracellular and intracellular compartments in vivo. For example, potassium (K + ) has a normal extracellular concentration in the extracellular compartment of blood between 3.6 and 5.2 mM. In contrast, the concentration of calcium inside red blood cells in vivo is typically between 80 and 120 mM. Sodium, on the other hand, has a normal extracellular concentration between 135 and 145 mM, while the normal sodium concentration inside red blood cells is about 12 mM. These differences are maintained by active transport through dedicated channels in the cell membrane or by the fact that the test substance is secreted by the cell into the extracellular phase and cannot cross the cell membrane.
[0003] Since most measurements of analytes in blood focus on extracellular concentrations, cell lysis, and especially hemolysis, can potentially have a dramatic effect on the measurement results. For example, if handling of a blood sample after it has been obtained causes significant hemolysis in the sample, subsequent measurements of the analyte may either overestimate the true extracellular concentration (if the analyte is more abundant in the intracellular compartment and cell lysis liberates the analyte, increasing its apparent concentration) or underestimate the true extracellular concentration (if the analyte is less abundant in the intracellular compartment and cell lysis dilutes the extracellular concentration).
[0004] Koseoglu M. et al., Biochemia Medica 2011;21(1):79-85, reported that the measurement of lactate dehydrogenase (LD) and aspartate aminotransferase (AST) was hindered by barely detectable hemolysis when using a single visual inspection (plasma hemoglobin <0.5 g / L). Clinically meaningful changes in potassium and total bilirubin were observed in moderately hemolyzed samples (hemoglobin >1 g / L). Concentrations of alanine aminotransferase (ALT), cholesterol, gamma-glutamyltransferase (GGT), and inorganic phosphate (P) were not hindered up to severely hemolyzed levels (hemoglobin: 2.5-4.5 g / L). Differences in albumin, alkaline phosphatase (ALP), amylase, chloride, HDL-cholesterol, creatine kinase (CK), glucose, magnesium, total protein, triglycerides, unsaturated iron-binding capacity (UIBC), and uric acid were statistically significant but remained within CLIA (Clinical Laboratory Improvement Amendments) limits. Clinically significant differences are defined as those greater than the total acceptable error (TAE) of the analyte established by CLIA in 1988. TAEs were as follows: + , ±0.5 mmol / L; AST, 20%; Mg, 25%; and LDH, 20%. The percentage of results within or outside the reference interval (RI) for each analyte was determined for each HI level. The RIs were as follows: K + , 3.5–5.3 mM; AST, 10–37 U / L; Mg, 1.60–2.40 mg / dl; and LDH, 84–246 U / L (see Validation of Haemolysis Index Thresholds Optimizes Detection of Clinically Significant Haemolysis, Tanu Goyal, MD,1 and Christine L. Schmotzer, MD1,2, Am J Clin Pathol 2015 April;143:579–583).
[0005] Currently, there are no international standards for dealing with the contribution of sample hemolysis to the measurement results, and most hospitals simply use thresholds set by the chemical analyzer manufacturer to determine whether a sample contains too high or too low concentrations of the analyte. All blood samples for analysis of hemolysis in samples are sent today to a central laboratory, where the analysis is performed on plasma samples. There are no commercial products on the market for the POC area and analysis of hemolysis in whole blood samples.
[0006] The current situation regarding the detection and identification of hemolysis in samples is described above. However, there is a need to inform users regarding the effect of hemolysis in samples in order to provide an indication regarding the true value of the measured parameters.
[0007] Attempts have been made to correct, for example, potassium concentrations measured in samples: "Correction Factors for Estimating Potassium Concentrations in Samples With In Vitro Haemolysis", Mai MHMansour, MS; Hassan MEAzzazy, PhD, DABCC; Steven C. Kazmierczak, PhD, DABCC, Arch Pathol Lab Med - Volume 133, June 2009. This 2009 article describes very precisely the situation and obstacles regarding potassium correction factors. The authors identified 744 items for review and 43 items for systematic review. The conclusion of the article is that the use of correction factors to estimate the true potassium concentration of samples with evidence of in vitro hemolysis is not recommended, which reflects even the current situation where potassium values are not corrected for hemolysis of samples.
[0008] WO 2018 / 121459 discloses a method for determining in vitro hemolysis and correcting at least one blood parameter of a blood sample by correcting for in vitro hemolysis. The technique disclosed in WO 2019 / 121459 does not provide for determining or correcting the contribution of the total number of cells lysed to the measured value of the test substance, e.g., the blood parameter. Summary of the Invention [Problem to be solved by the invention]
[0009] It is an object of embodiments of the present invention to provide a method, apparatus and computer program product for estimating the true extracellular concentration of an analyte in a sample and estimating the contribution of cell lysis, in particular hemolysis, to measurements of extracellular samples. [Means for solving the problem]
[0010] The present inventors have found that the introduction of intracellular marker measurements can be used to correct the measurements of extracellular analytes, thus allowing a corrected measurement of the analyte to be obtained directly, taking into account the effects of, for example, hemolysis on the measurement, in other words the method of the present invention provides a direct reference method that can provide a direct indication of the true extracellular concentration (or at least a more accurate estimate thereof) and the contribution of hemolysis to the measurement of the analyte.
[0011] Indeed, the inventors have demonstrated that at least the measurement of extracellular potassium can be corrected with high accuracy by subjecting the same sample to a series of tandem measurements of extracellular potassium and extracellular hemoglobin (also called cell-free hemoglobin or ccfHb). By deliberately lysing the cellular fraction of the sample in the intervals between tandem measurements, a set of measurements of potassium and ccfHb is obtained, which allows, for example, simple linear regression and subsequent extrapolation. This regression model then provides an estimate (in some embodiments, as a slope coefficient) of the contribution to the potassium measurement per unit of measured ccfHb. Then, in any subsequent measurement, the contribution due to cell lysis to any measurement can be determined, for example as the product between the measured ccfHb concentration and the slope coefficient, and the true extracellular value can also be derived, for example by simple subtraction.
[0012] Accordingly, a first aspect of the present invention provides a method for determining the effect of cell lysis on a measured concentration of an analyte present in a blood cell-containing liquid sample, the method comprising: A) measuring the concentration of a test substance in the extracellular phase of a sample comprising blood cells and measuring the concentration of an intracellular marker in the extracellular phase of the sample; B) then lysing a fraction of the blood cells and thereafter measuring the concentration of the test substance in the extracellular phase of the sample containing the lysed cells and the concentration of the intracellular marker; C) optionally repeating step B one or more times; and D) estimating a mathematical relationship between the concentration of the analyte and the change in concentration of the intracellular marker based on the set of measurements obtained in at least steps A to C, whereby the effect of cell lysis on the measured concentration of the analyte of the sample is determined by calculating the portion of the concentration of the analyte that originates from cell lysis from the measured concentration of the intracellular marker.
[0013] In a related second aspect, the present invention relates to a method of calibration of an apparatus for the determination of extracellular analyte concentrations, the method comprising the steps of performing with the apparatus the method of the first aspect of the invention and any embodiment thereof disclosed herein, storing in a memory module of the apparatus a mathematical equation of the relationship between analyte concentration and changes in the concentration of an intracellular marker as defined in relation to the first aspect of the invention, such that an output based on a subsequent measurement of the analyte performed by the apparatus is adjusted based on the measurement of the intracellular marker.
[0014] A third aspect of the invention relates to a method for determining an analyte concentration distribution in the extracellular phase of a sample, the method comprising the steps of measuring the total concentration of the analyte in the extracellular phase and measuring the concentration of an intracellular marker in the extracellular phase, and then estimating the contribution due to lysis of cells to the total concentration of the analyte and / or correcting the values of the measured analyte concentrations based on the measured concentrations of the intracellular marker, wherein a mathematical relationship between the analyte concentrations and the concentrations of the intracellular marker has been established according to the method of the first or second aspect of the invention as well as any embodiment thereof disclosed herein.
[0015] A fourth aspect of the invention relates to an apparatus for determining the concentration distribution of a test substance in the extracellular phase of a sample, the apparatus being configured to measure the total concentration of the test substance in the extracellular phase, to measure the concentration of an intracellular marker in the extracellular phase, and then to estimate, e.g. calculate, the contribution due to cellular lysis to the total concentration of the test substance by interpolation or extrapolation from the measured concentrations of the intracellular marker based on a mathematical or functional relationship between the concentrations of the test substance and the concentrations of the intracellular marker.
[0016] A fifth aspect of the invention relates to a computer program or computer program product comprising instructions for causing an apparatus of the fourth aspect to measure the total concentration of a test substance in the extracellular phase of a sample, to measure the concentration of an intracellular marker in the extracellular phase of the sample, and then to estimate, e.g. calculate, by interpolation or extrapolation, the contribution due to cellular lysis to the total concentration of the test substance from the measured concentrations of the intracellular marker based on a mathematical or functional relationship between the concentrations of the test substance and the concentrations of the intracellular marker.
[0017] A sixth aspect of the present invention is a method for producing a composition comprising the steps of: a) obtaining a first concentration in the form of a first total concentration of a test substance in the extracellular phase of the sample, and a first concentration of an intracellular marker in the extracellular phase of the sample; b) obtaining a second concentration of the test substance in the extracellular phase of the same sample, and a second concentration in the form of a second concentration of an intracellular marker, wherein a cellular fraction of the sample is lysed prior to obtaining the second concentration; c) estimating a relationship between the concentration of the test substance and the change in concentration of the intracellular marker based on at least the first and second concentrations obtained in steps a) and b).
[0018] In another form of the sixth aspect, there is provided a computer-implemented method for determining the effect of cell lysis on a measured concentration of an analyte present in a blood cell-containing liquid sample, the method comprising: A) obtaining the concentration of a test substance in the extracellular phase of a sample comprising blood cells and measuring the concentration of an intracellular marker in the extracellular phase of the sample; B) then lysing a fraction of the blood cells and thereafter obtaining the concentration of the test substance in the extracellular phase of the sample containing the lysed cells and the concentration of the intracellular marker; C) optionally repeating step B one or more times; and D) estimating a mathematical or functional relationship between the change in the concentration of the test substance and the concentration of the intracellular marker based on at least the set of measurements obtained in steps A to C; Thereby, a method is presented in which the effect of cell lysis on the measured concentration of an analyte in a sample is determined by estimating, eg, calculating, the portion of the analyte concentration that results from cell lysis from the measured concentration of an intracellular marker. [Brief description of the drawings]
[0019] [Figure 1] FIG. 13 is a graph showing the correlation of K+ and ccfHb measurements. [Diagram 2] 1 is a schematic diagram of an electrical circuit for ion / electrolyte potentiometric measurement. [Diagram 3] FIG. 1 shows in schematic form the principle behind the method and device for measuring ccfHb. [Figure 4] FIG. 1 is a schematic diagram of an exemplary apparatus for determining the analyte concentration distribution in the extracellular phase of a (liquid) sample. [Diagram 5] FIG. 5 shows a portion of an embodiment of an instrument similar to the apparatus of FIG. 4, but the instrument shown in FIG. 5 further includes a lysing unit arranged to lyse a fraction of blood cells. [Figure 6] FIG. 6 shows another embodiment of an apparatus similar to that of FIG. 4, but further including a lysis unit positioned to lyse a fraction of blood cells present in the chamber of the sensor. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] definition In the present context, an "analyte" is any chemical substance, composition, or moiety (or the activity of such a chemical substance, composition, or moiety) that is of interest for determination in a sample. Typical analytes of interest are those that can be or will be affected by the process of cell lysis in the sample (see Background Art above), since there is a significant difference between the intracellular and extracellular concentrations of the analyte. A non-exhaustive list of analytes is provided below in Table A. Thus, typical analytes are electrolytes and their associated ions, extracellular enzymes, and other biomolecules.
[0021] As used herein, an "intracellular marker" is a substance that is present in a very small or substantially constant amount in the extracellular phase in healthy individuals in vivo and that appears to be at a different, higher concentration in the intracellular phase. One example is hemoglobin, which is normally restricted to the cytoplasm of red blood cells and only appears in significant amounts in the extracellular phase when the red blood cell membrane is disrupted, i.e., when there is some degree of hemolysis (i.e., lysis of red blood cells). However, in principle, any substance that is restricted to the cytoplasm of living, healthy cells can act as an intracellular marker, as long as it allows the determination of its extracellular concentration with the required fidelity. The main advantage of employing hemoglobin as an intracellular marker is its abundance in whole blood, where red blood cells constitute an average of 43% v / v in healthy individuals.
[0022] Similarly, an "extracellular marker" is a substance that is present in a very small or substantially constant amount in the intracellular phase in healthy individuals in vivo and that appears to be at a different, higher concentration in the extracellular phase. One example is albumin, which in its nature as the most abundant plasma protein is usually restricted to plasma / serum. However, in principle, any substance that is restricted to the extracellular phase of a living, healthy individual can act as an extracellular marker, as long as it allows the determination of its intracellular concentration with the required fidelity.
[0023] The expression "effect of cell lysis" refers to a positive or negative (or variable) change in the concentration of the test substance located in the extracellular compartment, which change in concentration is the result of cell disintegration (i.e. cell lysis), thereby adding the test substance to the extracellular compartment (if the test substance is present in a higher concentration intracellularly than extracellularly) or thereby diluting the test substance (if the test substance is present in a lower concentration intracellularly than extracellularly).
[0024] Specific embodiments of the present invention First aspect of the present invention This embodiment relates to a method for determining the effect of cell lysis on a measured concentration of a test substance present in a blood cell-containing liquid sample (e.g. a blood sample or a diluted blood sample), comprising the steps of: A) measuring the concentration of the test substance in the extracellular phase of the sample comprising blood cells and measuring the concentration of an intracellular marker in the extracellular phase of the sample; B) then lysing a fraction of the blood cells and thereafter measuring the concentration of the test substance in the extracellular phase of the sample comprising the lysed cells and the concentration of the intracellular marker; C) optionally repeating step B one or more times; and D) estimating a mathematical relationship between the change in the concentration of the test substance and the concentration of the intracellular marker based on the set of measurements obtained in at least steps A to C, Thereby, the effect of cell lysis on the measured concentration of an analyte in a sample is determined by calculating the portion of the analyte concentration that results from cell lysis from the measured concentration of the intracellular marker.
[0025] Accordingly, this embodiment relates to a method for the determination of the effect of cell lysis on the measured concentration of a test substance present in a blood cell-containing liquid sample (e.g. a blood sample or a diluted blood sample), comprising the steps of: A) measuring the concentration of the test substance in the extracellular phase of a sample (e.g. obtained from an individual), wherein the sample comprises blood cells and measuring the concentration of an intracellular marker in the extracellular phase of the sample; B) then lysing a fraction of the blood cells of the same sample, whereby the concentration of the test substance and the concentration of the intracellular marker are measured in the extracellular phase of the same sample comprising the newly lysed cells; C) optionally repeating step B one or more times; and D) estimating the relationship between the change in the concentration of the test substance and the concentration of the intracellular marker based on the set of measurements obtained in at least steps A to C, Thereby, the effect of cell lysis on the measured concentration of an analyte in a sample is determined by calculating the portion of the analyte concentration that results from cell lysis from the measured concentration of the intracellular marker.
[0026] An important feature of the method of the first aspect of the invention is the application of performing a series of lysis performed in steps B and C. In the prior art method disclosed in WO 2019 / 121459, it is described to derive a conversion factor to convert the degree of in vitro hemolysis into the corresponding units of blood parameters. According to WO 2019 / 121459, this conversion factor is determined by using a series of samples with known amounts of hemolysis, for example by mixing a non-hemolyzed sample with a fully hemolyzed sample to introduce a known amount of, for example, free hemoglobin into the non-hemolyzed sample. The present invention avoids this derivation step by simply correlating the different degrees of determined hemolysis with the different determined values of the analyte, without any prior knowledge of the degree of hemolysis of the sample and without the need to establish a series of mixed samples from fully hemolyzed and non-hemolyzed samples.
[0027] It should be noted that both intracellular and extracellular markers (see definition above) can be used according to the invention. For intracellular markers, the concentration in the extracellular phase increases as a result of cell lysis, whereas extracellular markers will show a decrease in concentration as a result of cell lysis, but for both cases a correlation with the measured concentration of the analyte can be established. Thus, although the use of intracellular markers is preferred (due to the ease of detecting deviations from very low extracellular values), all the following disclosures regarding correlations with intracellular markers can be applied mutatis mutandis to appropriately selected extracellular markers, with the understanding that an increase in the measured intracellular marker concentration can be translated into a decrease in the measured extracellular marker concentration.
[0028] Step D can be performed, for example, by using the set of measurements obtained in steps A to C to define in a regression model or curve fitting model in the form of a function in which the concentration of the test substance is the dependent variable and the concentration of the intracellular marker is the independent variable, the relationship between the concentration of the test substance and the change in the concentration of the intracellular marker; The effect of cell lysis on the measured concentration of the analyte in the sample is then determined by calculating the portion of the analyte concentration that results from cell lysis from the measured concentration of the intracellular marker.
[0029] In fact, the method of the first aspect allows to establish a relationship between the measured value of the intracellular marker and the concentration / amount of the analyte in a given measurement setup or measuring device. Thus, the measurement of step A of the method of the first aspect will serve as a baseline, and a value will typically be subtracted from the corresponding measurements made in steps B and C. Thereby, each given increase (ΔI) in the value of the intracellular marker above the baseline value can be paired with a corresponding change (Δa) in the measured value of the analyte. Thus, while this allows the determination of the "true" extracellular value of the sample examined in the first aspect and the effect of cell lysis, the most interesting result is the establishment of a general relationship between the measured value of the intracellular marker and the measured value of the analyte, thereby allowing the realization of the invention discussed in the third aspect of the invention below, in which only the determination in the sample of the amount / concentration of the analyte and the intracellular marker is necessary, since the measured value of the analyte can be subjected to correction using the results obtained from the first aspect of the invention.
[0030] Typically, the analyte is an ion or electrolyte, such as one that is routinely measured in determining the concentration of an electrolyte in a blood sample. Thus, the analyte is typically an ion or electrolyte, such as an electrolyte in a blood sample. + , Na + , Ca 2+ , Mg 2+ , Cl - In particular, the analyte is an ion selected from the group consisting of K + It is.
[0031] The test substance can also be a non-electrolyte, such as lactate dehydrogenase (LD), aspartate aminotransferase (AST), bilirubin, albumin, alkaline phosphatase (ALP), amylase, HDL-cholesterol, creatinine kinase (CK), glucose, serum or plasma total protein, triglycerides, unsaturated iron binding capacity (UIBC), and uric acid.
[0032] Generally, test substances are selected from those shown in Table A, which also shows the effects (positive, variable, or negative) and basic sources of bias caused by cell lysis (especially hemolysis).
[0033] [Table 1] The method of the first aspect can be performed on any cell-containing sample in which it is worthwhile to determine the extracellular concentration of the test substance, although the preferred extracellular phases are serum or plasma, either from a non-human animal or from humans, and both of these extracellular phases may be diluted to facilitate measurement when performing the method, in which case the measurement will need to be adjusted for the degree of dilution.
[0034] When the sample being examined is blood and the extracellular phase is serum or plasma, the method of the present invention provides an indication of hemolysis, where other cells in the blood are present at very low concentrations compared to the concentration of red blood cells and the contribution from the lysis of these cells (i.e. mainly white blood cells) is negligible.
[0035] Of course, the preferred intracellular marker is hemoglobin or a hemoglobin derivative, especially cell-free hemoglobin (ccfHb). The estimated mathematical relationship, e.g., the function established by the regression model or curve fitting model described above, is in some embodiments a linear function f(I)=a×I+b, where f(I) is the measured concentration of the analyte, I is the measured concentration of the intracellular marker, b is the extracellular concentration of the analyte without cell lysis, and a is the amount of change in the extracellular concentration of the analyte per unit of concentration of the intracellular marker (slope coefficient). When adopting this simple model, which assumes that a simple linear relationship exists between the release of hemoglobin due to cell lysis and the change in the concentration of the analyte, the contribution due to cell lysis is calculated as a×I. In other words, in this simple model, the only constant of relevance for determining the effect of cell lysis and the "true" extracellular concentration of the analyte is the slope coefficient a. Importantly, because the change in hemoglobin (Hb) content in individual red blood cells is very limited, the initial determination of the slope coefficient a allows for multiple subsequent measurements of the analyte, and the contribution due to cell lysis can be easily determined.
[0036] For a linear relationship, the number of measurements in steps B and C can in principle be as little as one, assuming that there is a data point (0,0) (i.e. zero intracellular markers and zero analyte). In that case, the relationship that can be derived is a×I, with b set to zero. This simple function therefore only represents the contribution due to cell lysis. However, it is preferred that a larger number of measurements are made to derive a×I of the a×I+b relationship, and referring to FIG. 1, K + We performed 479 tests for β-lactamase inhibitors (CCL) and ccfHb, with each test containing three measurements. In short, the more measurement points, the more accurate the regression model (R 2 =0.9907). Typically the total amount of measurements in steps B and C will be at least 3.
[0037] However, in some cases, the regression or curve-fitting model may need to be non-linear. For example, if the analyte itself is bound to the intracellular marker at equilibrium, the gradual release of the intracellular marker need not be accompanied by a linear increase or decrease in the analyte concentration. However, it is possible to determine whether such more complex events are relevant and derive the best non-linear regression model for that purpose.
[0038] In practice, the deliberate lysis of cells in steps B and C can be achieved by any practical method known in the art, such as physical treatment of the sample selected from the group consisting of mechanical shearing, such as homogenization or bead milling, sonication, freeze-thaw treatment, heating, osmotic shock treatment, and cavitation. Alternatively, the chemical treatment is selected from the group consisting of detergent treatment, alkali treatment, and enzyme treatment. Since chemical treatment inherently dilutes the test sample, appropriate corrections for dilution may need to be included in the measurement of the concentrations of the analyte and intracellular markers.
[0039] Importantly, lysis of the cells can be performed after obtaining the sample from the subject, and furthermore, some of the test substance of interest will, after some time, begin to equilibrate between the intracellular and extracellular compartments due to reduced activity of active transport mechanisms across the cell membrane of the cells of the sample. The time that elapses before such equilibration occurs depends, inter alia, on the temperature, with low temperatures being able to slow down passive transport across cell membranes. Thus, preferably, a sample comprising blood cells is obtained from a subject, preferably a human subject, and the interval period between obtaining the sample from the subject and performing steps A-D is short enough to prevent the concentration of the test substance from equilibrating to a significant extent between the extracellular and intracellular phases of the sample. This time interval is typically <1 hour, e.g. <55 min, <50 min, <45 min, <40 min, <35 min, <30 min, <25 min, <20 min, <15 min, <10 min, <9 min, <8 min, <7 min, <6 min, <5 min, <4 min, <3 min, <2 min, <1 min, and preferably between 5 and 55 seconds, between 5 and 50 seconds, between 5 and 45 seconds, between 10 and 45 seconds, and between 15 and 45 seconds. In short, the more quickly the sample is subjected to the method of the first aspect of the invention, the more accurate the regression model will be to provide an accurate determination of the effect of cell lysis.
[0040] A distinctive feature of the first aspect of the invention is that it can be performed for multiple analytes in parallel, where the effect on the measured concentration of each one of the multiple analytes is determined, and step D defines a relationship between the concentration of each of the multiple analytes and the change in the concentration of the intracellular marker. In practice, the samples are processed as described above in the embodiment of the first aspect, but instead of just establishing one regression model, multiple regression models are established for each analyte. For example, samples may be processed for multiple analytes, where the effect on the measured concentration of each one of the multiple analytes is determined, and step D defines a relationship between the concentration of each of the multiple analytes and the change in the concentration of the intracellular marker. + , Na + , Ca 2+ , and ccfHb can be tested multiple times, and the measured ccfHb value is + , Na + , and Ca 2+ A regression model is fitted to the values of
[0041] Advantageously, the method of the first aspect is carried out in an apparatus adapted to measure the concentration of the intracellular marker and the concentration of the analyte, or, where appropriate, multiple analytes. This will facilitate rapid and efficient measurement and readout of the results. However, although not preferred, the invention can also be carried out in at least two separate apparatuses, one of which is adapted to measure the concentration of the intracellular marker and the other of which is adapted to measure the analyte, or, where appropriate, multiple analytes. The latter requires that the calculation of the effect of cell lysis is then performed manually based on the readout from the at least two separate apparatuses, or that the measurements are all entered (manually or by communication means) at one point in time into the same apparatus which performs the necessary calculations.
[0042] Typically, an apparatus for carrying out the method of the first aspect comprises: an inlet for an acellular liquid that includes or consists of extracellular phase material; or It includes an inlet for a sample containing both extracellular phase material and blood cells, and the device further includes means for separating the cells from the extracellular phase.
[0043] If the sample is a blood sample, the cells can be separated from the sample input to the measuring device before the extracellular phase material is introduced into the device, but the device can also include the necessary separation module, such as a filter unit or a centrifuge (which allows the cells to settle and the extracellular material to be removed from the settled cells) or a coating membrane. Alternatively, the cells can be removed by a porous mirror or isoacoustic focusing as described in Augustsson, P., Karlsen, J., Su, HW. et al. Iso-acoustic focusing of cells for size-insensitive acousto-mechanical phenotyping, Nat Commun 7, 11556 (2016).
[0044] Second Aspect of the Invention This aspect relates to a method for the calibration of an apparatus for the determination of extracellular analyte concentrations, the method comprising the steps of performing by the apparatus any one of the methods of the first aspect of the invention and any embodiment thereof disclosed herein, storing in a memory module of the apparatus constant values characterizing the functions defined in the first aspect of the invention and any embodiment thereof discussed herein, such that an output based on a subsequent measurement of the analyte performed by the apparatus is adjusted based on the measurement of an intracellular marker.
[0045] Thus, as explained above, the device can be calibrated at an initial stage, the method of the first aspect of the invention is performed, and the necessary constants or curve-fit data derived from the regression model / curve-fit model are then stored in the device's memory. If subsequent measurements of the analyte are performed and recorded on the device, and the results of the corresponding measurements of the intracellular markers are also recorded on the device, the end user can obtain information on the total amount of analyte in the extracellular compartment of the sample, as well as information on the contribution due to lysed cells. This then allows for a more accurate clinical evaluation of the data, since in most cases cell lysis is performed during sampling, and the contribution due to this artifact can already be excluded at the measurement stage, and seemingly clinically relevant deviations of the measured analyte concentration from normal values can be limited by the suggestion that the measurement result was affected by cell lysis. Similarly, seemingly normal values of the measured analyte can be noted as clinically relevant after the results have been decomposed into "true" values and cell lysis contribution values. In other words, the method of the first aspect of the invention allows the measurement of the analyte to provide more accurate results for the clinician to take into account, see also the third aspect of the invention.
[0046] Third aspect of the present invention In accordance with the above, this aspect provides a method for the determination of a test substance concentration distribution in the extracellular phase of a sample, the method comprising the steps of measuring the total concentration of the test substance in the extracellular phase, measuring the concentration of an intracellular marker in the extracellular phase, and then calculating the contribution due to cellular lysis to the total concentration of the test substance by interpolation or extrapolation from the measured concentration of the intracellular marker, wherein a mathematical relationship between the test substance concentration and the concentration of the intracellular marker has been established according to the method of the first and / or second aspect of the invention and any embodiment thereof disclosed herein.
[0047] According to the method of the first aspect and embodiments thereof, determining such analyte concentration distribution should preferably be performed so as to avoid that the analyte is subject to equilibration between the intracellular and extracellular compartments, or at least such equilibration does not exceed what was the case when performing the methods of the first and second aspects of the invention and embodiments thereof. Thus, preferably, a sample comprising blood cells is obtained from a subject, preferably a human subject, and the interval period between obtaining the sample from the subject and performing the method of the third aspect of the invention is short enough to prevent the concentration of the analyte from equilibrating to a significant extent between the extracellular and intracellular phases of the sample, preferably the period is approximately the same as that utilised when determining the mathematical relationship according to the method of the first or second aspect of the invention. Again, the time intervals are typically <1 hour, e.g. <55 min, <50 min, <45 min, <40 min, <35 min, <30 min, <25 min, <20 min, <15 min, <10 min, <9 min, <8 min, <7 min, <6 min, <5 min, <4 min, <3 min, <2 min, <1 min, preferably between 5 and 55 seconds, between 5 and 50 seconds, between 5 and 45 seconds, between 10 and 45 seconds, and between 15 and 45 seconds. In short, the more quickly the sample is subjected to the method of the third aspect of the invention, the more accurate the determination of the contribution due to cell lysis and the more accurate the correction of the analyte measurement will be.
[0048] As stated in the second embodiment, the determination of the analyte concentration distribution provides the skilled artisan with a much more accurate set of data for subsequent decisions to be made in a clinical setting. Fourth aspect of the present invention This aspect relates to an apparatus for determining the concentration distribution of a test substance in the extracellular phase of a sample (e.g. a measurement sample), wherein the apparatus is configured to measure the total concentration of the test substance in the extracellular phase, to measure the concentration of an intracellular marker in the extracellular phase, and then to estimate, e.g. calculate, the contribution due to cellular lysis to the total concentration of the test substance by interpolation or extrapolation from the measured concentrations of the intracellular marker based on a mathematical or functional relationship between the concentrations of the test substance and the concentrations of the intracellular marker, e.g. established according to the method of any one of the first and second aspects.
[0049] The device may be advantageous for enabling the true extracellular concentration of an analyte of a sample to be determined, for example the extracellular concentration of an analyte of a sample that ignores the contribution due to lysis of cells to the total concentration of the analyte.
[0050] A "sample", e.g. a measurement sample, may in the present context be understood to be a sample in which the true extracellular concentration of the analyte is determined. "Apparatus" is understood to encompass both distributed apparatus, for example a system including multiple separate (subordinate) apparatus, and a unitary apparatus, for example a unit in a single casing.
[0051] The device may in an embodiment be a unit, for example contained in a single casing, optionally with a single sample inlet and / or a common sample inlet for the sample in which the concentration of the intracellular marker and the concentration of the analyte are to be measured.
[0052] The device may in embodiments be understood to be a distributed device (e.g. a system), e.g. two or more physically separate (slave) devices, which may be digitally connected to each other and / or to a data processing unit, e.g. arranged to estimate, e.g. calculate, by interpolation or extrapolation, the contribution due to lysis of cells to the total concentration of the analyte from the measured concentrations of the intracellular marker based on a mathematical or functional relationship between the concentrations of the analyte and the concentrations of the intracellular marker.
[0053] The device may comprise (slave) devices adapted for measuring the concentration of an intracellular marker and an analyte, or, where appropriate, the concentration of multiple analytes. The device may comprise at least two separate (slave) devices, one of which is adapted for measuring the concentration of an intracellular marker and the remaining of the at least two (slave) devices is adapted for measuring a test substance, or, if appropriate, multiple test substances.
[0054] The device is an inlet for an acellular liquid that includes or consists of extracellular phase material; or It may include an inlet for a sample containing both extracellular phase material and blood cells, and the device further includes a means for separating the cells from the extracellular phase, for example the means for separating the cells from the extracellular phase is selected from a filter (e.g. a porous mirror (PM)) or a centrifuge or a porous mirror or isoacoustic focusing.
[0055] The device may include, or be operatively linked to, a memory module that stores values characterizing the mathematical or functional relationship, e.g., so that output based on measurements of test substances performed by the device is adjusted based on the mathematical or functional relationship and based on measurements of intracellular markers.
[0056] According to an embodiment, the apparatus comprises: I) the device receives, optionally consecutively, a number of blood cell-containing liquid samples, the number of blood cell-containing liquid samples differing from one another in fractions of lysed blood cells; II) the device measures the concentration of the analyte in the extracellular phase from each sample containing blood cells and measures the concentration of an intracellular marker in the extracellular phase from each sample; III) The device, for example by an external unit, for example by cloud computing, uses the set of measurements obtained in step II to determine a mathematical or functional relationship in a regression model or curve fitting model in the form of a function in which the concentration of the analyte is the dependent variable and the concentration of the intracellular marker is the independent variable, the relationship being between the concentration of the analyte and the change in the concentration of the intracellular marker; The method is further configured to determine a mathematical or functional relationship by determining the effect of lysis of the cells on a measured concentration of an analyte present in the blood cell-containing fluid sample.
[0057] By "apparatus defined" in step III, it is understood that apparatus may encompass a distributed system, e.g. an apparatus or part of an apparatus arranged to define or which has defined a mathematical or functional relationship, e.g. by requiring another piece of apparatus or another unit to perform the definition of the mathematical or functional relationship.
[0058] According to this (calibration) embodiment, the device is further arranged to receive multiple samples with differing lysis fractions, optionally simultaneously or sequentially, e.g. a blood sample is aliquoted and each aliquot is lysed (optionally manually) to a specific extent, or sub-samples are removed from the sample and lysed (optionally manually) to a progressively greater extent between removal of each sub-sample, and the aliquots or sub-samples are fed simultaneously or sequentially to the device.
[0059] A "(blood cell-containing fluid) sample", e.g. a (blood cell-containing fluid) sample which is a calibration sample, may in the present context be understood as a sample used to determine (calibrate) a mathematical or functional relationship. This (calibration) sample may or may not be identical to the (measurement) sample in which the true extracellular concentration of the analyte is determined. Thus, the multiple blood cell-containing fluid (calibration) samples may be derived from the same (measurement) sample in which the true extracellular concentration of the analyte is measured (in which case the mathematical or functional relationship is expected to be most accurate) or may be a separate sample from the (measurement) sample (in which case the relationship is expected to be an approximation).
[0060] According to an embodiment, the apparatus comprises: i) a device receiving a blood cell-containing liquid sample; ii) the device measures a concentration of the analyte in the extracellular phase from the sample or a portion thereof comprising blood cells, and measures a concentration of an intracellular marker from the sample or a portion thereof comprising blood cells; iii) the device lyses a fraction of blood cells and then measures the concentration of the analyte and the concentration of the intracellular marker in the extracellular phase of the sample containing the lysed cells; iv) the device optionally repeats step iii one or more times; and v) The device, for example by an external unit, for example by cloud computing, uses the set of measurements obtained in steps ii to iv to determine a mathematical or functional relationship in a regression model or curve fitting model in the form of a function in which the concentration of the analyte is the dependent variable and the concentration of the intracellular marker is the independent variable, the relationship being between the concentration of the analyte and the change in the concentration of the intracellular marker; The method is further configured to determine a mathematical or functional relationship by determining the effect of lysis of the cells on a measured concentration of an analyte present in the blood cell-containing fluid sample.
[0061] By "apparatus defined" in step V, it is understood that apparatus may encompass a distributed system, e.g. an apparatus or part of an apparatus arranged to define or which has defined a mathematical or functional relationship, e.g. by requiring another piece of apparatus or another unit to perform the definition of the mathematical or functional relationship.
[0062] According to this (calibration) embodiment, the device is further arranged to receive the sample, (optionally manually) lyse various fractions of blood cells, and measure the corresponding values of the analyte and intracellular markers. A possible advantage of this embodiment may be that the calibration and / or the determination of the mathematical or functional relationships may be done faster, involve less (human) resources, and / or be more robust. Lysis may be done by an instrument, for example by application of heat, shear forces, shaking, pressure changes or cavitation or ultrasound, for example the instrument includes a heating unit, a narrow or capillary channel, a vortex mixer, a channel with a narrowing portion to induce a pressure change (e.g. cavitation) as a fluid passes through the channel, a piston connected to an enclosed space, and / or an ultrasound source.
[0063] According to one embodiment, the device comprises an optical measurement setup, e.g. comprising a porous mirror (PM), arranged to measure the concentration of an intracellular marker in the extracellular phase, and / or an electroanalytical measurement setup, e.g. an ion-selective electrode sensor, e.g. an ion-selective membrane electrode sensor, for measuring the total concentration of the test substance in the extracellular phase.
[0064] Fifth aspect of the present invention According to this aspect there is provided a computer program or computer program product comprising instructions for causing the device of the fourth aspect to measure the total concentration of a test substance in the extracellular phase of a sample, to measure the concentration of an intracellular marker in the extracellular phase of the sample, and then to estimate, e.g. calculate, by interpolation or extrapolation, the contribution due to cellular lysis to the total concentration of the test substance from the measured concentrations of the intracellular marker based on a mathematical or functional relationship between the concentrations of the test substance and the concentrations of the intracellular marker.
[0065] According to an embodiment, a computer program or computer program product is provided for causing an apparatus of the fourth aspect to i) measuring the concentration of an analyte in the extracellular phase of a sample from each of a number of samples comprising blood cells, and measuring the concentration of an intracellular marker in the extracellular phase of each of the samples (and optionally having the device lyse the samples such that the fraction of cells lysed by samples of the number of samples differs from one another); and ii) may further comprise instructions for using the set of measurements obtained in step i to define a mathematical or functional relationship in a regression model or curve fitting model in the form of a function in which the concentration of the test substance is the dependent variable and the concentration of the intracellular marker is the independent variable, the relationship between the concentration of the test substance and the change in the concentration of the intracellular marker.
[0066] According to this aspect, the invention relates to a computer program or computer program product comprising instructions for causing an apparatus of the fourth aspect to perform certain steps, e.g. a computer program product adapted for causing a processor or computer system contained in the apparatus of the fourth aspect, including at least one computer having data storage means connected thereto, to control the apparatus of the fourth aspect. This aspect of the invention is particularly advantageous, but not limited to, in that the invention may be achieved by a computer program or computer program product which, when downloaded or uploaded to the apparatus, e.g. to a computer system contained in the apparatus of the fourth aspect, causes the apparatus of the fourth aspect to perform the operations of the apparatus. Such a computer program or computer program product may be provided on any kind of computer readable medium or provided over a network.
[0067] Considerations Pertaining to All Aspects of the Invention K + and other ions, Exemplary K + The measurement principle for electrolyte sensors in measuring devices (eg Radiometer's ABL90 FLEX analyzer) is based on electrochemical measurements.
[0068] Potentiometry: The potential of the electrode chain is measured by a voltmeter and is related to the concentration of the sample (Nernst equation). The potentiometric principle is to measure pH, pCO2 (pH measurement), K + , Na + , Ca 2+ , and Cl - It is applied in a sensor.
[0069] Strictly speaking, in potentiometry, the potential of the electrode chain is related to the activity of the substance, not its concentration, which can be thought of as the effective concentration of the species, taking into account the non-idealities of the medium.
[0070] Activity and concentration are related by ax=ycx, where ax is the activity of species x, y=activity coefficient of species x under the measurement conditions (for an ideal system y=1) and cx=concentration of species x (mol / L). Precisely speaking, activity relates to the molarity of species x (amount of solute substance (mol) divided by mass of solvent (kg). However, molarity is converted to concentration (molarity). The ABL90 FLEX analyzer automatically converts activity to concentration. The term "concentration" is therefore used in the description of the measurement principle of the respective sensor.
[0071] Potentiometric principle: pH and electrolyte sensors are measured according to the potentiometric principle, where the potential of an electrode chain recorded by a voltmeter is related to the concentration of the substance by the Nernst equation. Electrode Chain: The electrode chain (or electrical circuit) arrangement for measuring pH / electrolyte is shown in FIG.
[0072] As an alternative to the potentiometric principle described above, flame emission spectroscopy can be used (LJ Kricka, JY Park, Pathobiology of Human Disease, 2014). Flame emission spectroscopy is based on the characteristic emission by atoms of many metallic elements when given sufficient energy, such as that provided by a high-temperature flame. The wavelengths used to measure the elements depend on the selection of lines of sufficient intensity to give sufficient sensitivity, and on the absence of other interfering lines at or near the selected wavelengths. For example, in a flame, lithium produces a red color, sodium a yellow color, potassium a purple color, rubidium a red color, and magnesium a blue color. These colors are characteristic of metal atoms present as cations in solution. Under certain controlled conditions, the intensity of light at the characteristic wavelengths produced by each atom is directly proportional to the number of atoms releasing the energy, and thus to the concentration of the substance of interest in the sample. This technique was previously used for the analysis of sodium, potassium, and lithium in body fluids, but has been largely replaced by electrochemical techniques.
[0073] Measurement principle of ccfHb: Please refer to FIG. 3 which shows a schematic diagram of the structure of the Porous Mirror (PM) sensor. Briefly, Porous Mirror (PM) is a proprietary technology that provides optical absorption measurements of the plasma phase of a whole blood (WB) sample. It is used to determine the concentration of cell-free hemoglobin (ccfHb). It works by diffusing ccfHb into a porous PETP membrane whose pore size is smaller than that of red blood cells (RBCs). Thus, RBCs cannot enter the pores. The pores are dead-ended within the membrane and are separated by a distance of mm 2Each of the 1.2 million holes per microwell constitutes a nanocuvette (φ=400 nm, length=25 μm) in close proximity to the sample. ccfHb and other plasma components move to and from the nanocuvette by diffusion. The front side of the porous membrane (facing the sample) is coated with a noble metal (Pd, thickness=100 nm), while the ends of the holes facing the sample remain open. The metal layer on the front side of the membrane allows light reflection (mirror of PM) and transmission-like measurement of hemoglobin (Hb) in the holes from the rear side of the membrane. Advantageously, optical interference from Hb in the RBCs and / or other particulate matter of the sample is suppressed to negligible levels by the same optically blocking metal layer. The porous mirror device is a translucent slab having a front surface and a back surface facing opposite the front surface, the front surface being adapted for contact with a fluid; 1. A porous mirror for detection of an analyte in a fluid with an optical probe, comprising: a reflective layer on a front surface of a translucent slab, the reflective layer adapted to reflect light reaching the reflective layer from a rear surface of the translucent slab; the translucent slab includes holes, the holes being dead-end holes extending from respective openings in the front surface across the reflective layer into the translucent slab; It may be a porous mirror, where the cross-sectional dimensions of the openings of the holes are dimensioned to prevent larger particles or debris, if contained in the fluid, from entering the holes, while allowing the analyte in the fluid to enter the holes by diffusion. Porous mirror (PM) technology is described in WO 2017 / 085162 A1, which is hereby incorporated in its entirety, and is described, for example, in particular in claim 1 of WO 2017 / 085162 A1 and further in Figure 1 on pages 24-25 and the accompanying text.
[0074] Alternatively, a standard or reference method for the determination of hemoglobin concentration may be utilized, which is the HiCN method. Red blood cells are lysed by mixing blood with a solution consisting of potassium cyanide, potassium ferricyanide, and Drabkin's solution to produce a uniformly agitated hemoglobin solution. Potassium ferricyanide converts hemoglobin to methemoglobin (i.e., a hemoglobin derivative), which combines with potassium cyanide to produce hemoglobin cyanide (cyanmethemoglobin). Once the reaction is complete, the absorbance of the solution is studied in a spectrophotometer at 540 nanometers. Hemoglobin cyanide has a broad absorbance peak at this wavelength. The absorbance is compared to that of a standard hemoglobin cyanide solution, and the amount of hemoglobin is obtained using the formula:
[0075] This method is the method of choice for the estimation of hemoglobin and is recommended by the International Committee for Standardization of Hematology, since it converts all types of hemoglobin to cyanmethemoglobin (except sulfhemoglobin) and stable and reliable standards are available. EXAMPLES
[0076] Exemplary Apparatus FIG. 4 is a schematic diagram of an exemplary device 100 for the determination of an analyte concentration distribution in the extracellular phase of a (liquid) sample (e.g. measurement sample) 102 comprising an analyte and an intracellular marker, which is acellular hemoglobin, the device being configured to measure the total concentration of the analyte in the extracellular phase, to measure the concentration of the intracellular marker in the extracellular phase, and then to estimate, e.g. calculate, by interpolation or extrapolation, from the measured concentrations of the intracellular marker, e.g. based on a mathematical or functional relationship between the analyte concentration and the concentration of the intracellular marker, e.g. established according to the method of any one of the first and second aspects, the device One or more sensors (or slave devices) 104, the concentration of the analyte in the liquid sample, and A sensor for measuring the cell-free hemoglobin concentration of a liquid sample; The data processing device 106 includes a processor configured to measure the total concentration of the test substance in the extracellular phase, measure the concentration of an intracellular marker in the extracellular phase, and then estimate, e.g. calculate, by interpolation or extrapolation, the contribution due to cellular lysis to the total concentration of the test substance from the measured concentrations of the intracellular marker based on a mathematical or functional relationship between the concentrations of the test substance and the concentrations of the intracellular marker.
[0077] In the illustrated embodiment, the one or more sensors 104 include two sensors for measuring the analyte concentration of the liquid sample and the cell-free hemoglobin concentration of the liquid sample, respectively. The schematic diagram of Fig. 4 further shows the liquid sample inlet 112, the microfluidic system 114, the memory module 116, and the user interface 118, which includes an output unit 120 arranged to visually output information regarding any one or more or all of the following: the total concentration of the analyte, the concentration of the intracellular marker, the contribution of the lysis of cells to the total concentration of the analyte, the true concentration of the intracellular marker, and the mathematical or functional relationship. The thin arrows indicate the flow of information from the one or more sensors 104 to the data processing device 106, such as the analyte concentration of the liquid sample and the cell-free hemoglobin concentration of the liquid sample, and the output signal from the data processing device 106 to the unit interface 118 (more specifically the output unit 120).
[0078] FIG. 5 shows a portion of an embodiment of an instrument similar to that of FIG. 4 including the same features, and like reference numerals indicate like features, but the instrument shown in FIG. 5 further includes a chamber with a lysing unit 532, e.g., a lysing element, arranged to lyse a fraction of blood cells (of the sample or a portion thereof). The instrument of FIG. 5 further includes a sample container 530. In the particular embodiment shown in FIG. 5, the lysing unit includes a lysing element in the form of a heating device 534 arranged to heat the sample in the lysing unit, although the heating device could be replaced by, e.g., an ultrasonic device, one or more capillary tubes, a vortex mixer, or a piston. In use, the sample may be maintained in the sample container, and portions of the sample may be continuously moved or drawn through the lysing unit, the portions of which may be lysed to various extents, e.g., a first portion may be lysed to zero or a minimal extent by the inactive lysing unit 532 during the movement of the portion through the lysing unit, while a subsequent portion may be lysed to an even greater extent by the active lysing unit during the movement of the portion through the lysing unit (e.g., by increasing the temperature or extending the time of the sample in the lysing unit). After migration through the lysis unit, the concentration of the analyte in the extracellular phase of the sample containing the lysed cells and the concentration of the intracellular marker are measured.
[0079] In another embodiment (not shown), the separate sample container 530 can be omitted, e.g., in favor of a lysis unit that surpasses the function of a separate sample container, e.g., the sample is maintained in the lysis unit and lysed there (over time) to an even greater extent, while simultaneously portions of the sample are continuously withdrawn from the lysis unit, thereby obtaining spatially and temporally separated sample portions with different fractions of lysed cells.
[0080] FIG. 6 shows another embodiment of an instrument similar to the device of FIG. 4 including the same features, and like reference numbers indicate like features, but the instrument shown in FIG. 6 further includes a lysis unit 632 arranged to lyse a fraction of blood cells (of the sample or part thereof). In FIG. 6, the chamber of the lysis unit may serve the function of the separate sample container of FIG. 5 and may include elements for both lysis and measurement, such as a lysis element and a sensor 104. In the instrument of FIG. 6, the lysis unit is arranged to lyse a fraction of blood cells that are in the chamber of the sensor 104 (which may also be the chamber of the lysis unit). In the particular embodiment shown in FIG. 6, the lysis unit includes a lysis element in the form of an ultrasound source 636 arranged to expose the sample to ultrasound, but the ultrasound source may be replaced by, for example, a heater, a capillary tube, a vortex mixer, or a piston. In use, the sample may be maintained in the chamber of the sensor and the sample may be lysed to different extents between successive measurements, for example a first measurement may be performed first while the sample is lysed to zero or a minimal extent by the lysis unit 632, for example due to an inactive lysis unit before and during that first measurement, while before or during subsequent measurements the sample is lysed to an even greater extent, for example due to an active lysis unit, with the sample being lysed to an increased extent as a result over time between (and optionally during) the measurements. The measurements include determining the concentration of the analyte and the concentration of the intracellular marker in the extracellular phase of the sample comprising the lysed cells.
Claims
1. 1. A method for determining the effect of cell lysis on a measured concentration of an analyte present in a blood cell-containing liquid sample, said method comprising: A) measuring the concentration of a test substance in the extracellular phase of a sample comprising blood cells and measuring the concentration of an intracellular marker in the extracellular phase of said sample; B) then lysing a fraction of said blood cells and thereafter measuring the concentration of said test substance and the concentration of said intracellular marker in the extracellular phase of the sample containing the lysed cells; C) optionally repeating step B one or more times; and D) estimating a mathematical relationship between the concentration of the test substance and the change in concentration of the intracellular marker based on at least the set of measurements obtained in steps A to C; A method whereby the effect of cell lysis on the measured concentration of the analyte in a sample is determined by calculating the portion of the analyte concentration that originates from cell lysis from the measured concentration of the intracellular marker.
2. The method of claim 1 , wherein the test substance is an ion or an electrolyte.
3. The test substance is K + , Na + , Ca 2+ , Mg 2+ , and Cl - Ions selected from the group consisting of: + The method of claim 2, which is or comprises:
4. 2. The method of claim 1, wherein the test substance is a non-electrolyte selected from the group consisting of lactate dehydrogenase (LD), aspartate aminotransferase (AST), bilirubin, albumin, alkaline phosphatase (ALP), amylase, HDL-cholesterol, creatine kinase (CK), glucose, serum or plasma total protein, triglyceride, unsaturated iron binding capacity (UIBC), and uric acid.
5. The method according to any one of claims 1 to 4, wherein the sample in step A is an optionally diluted blood sample.
6. The method according to any one of claims 1 to 5, wherein the cell lysis is hemolysis.
7. The method according to any one of claims 1 to 6, wherein the intracellular marker is hemoglobin or a hemoglobin derivative.
8. The method of claim 7, wherein the intracellular marker is cell-free hemoglobin.
9. The method according to any one of claims 1 to 8, wherein the lysis of cells in steps B and C is a physical treatment selected from the group consisting of mechanical shearing such as homogenization or bead mill treatment, ultrasonic treatment, freeze-thaw treatment, heating, osmotic shock treatment, and cavitation, or a chemical treatment selected from the group consisting of detergent treatment, alkali treatment, and enzyme treatment.
10. 10. The method according to any one of claims 1 to 9, wherein the sample comprising blood cells is obtained from a subject, preferably a human subject, and the interval period between obtaining the sample from the subject and performing steps A to D is sufficiently short to prevent the concentration of the test substance from equilibrating to a significant extent between the extracellular and intracellular phases of the sample.
11. 11. The method according to claim 1, wherein the effect on the measured concentration of each one of a number of test substances is determined, and step D defines a relationship between the concentration of each of the number of test substances and the change in the concentration of the intracellular marker.
12. The method according to any one of claims 1 to 11, wherein step B is performed one or more times on the same sample from one individual.
13. The method according to any one of claims 1 to 12, wherein it is the total effect of cytolysis on the measured concentration, determined by calculating the portion of the test substance concentration that comes from the total amount of cytolysis.
14. 1. A method of calibration of an apparatus for the determination of extracellular analyte concentrations, said method comprising: and to adjust an output based on a subsequent measurement of the test substance performed by the device based on the measurement of the intracellular marker. Carrying out the method according to any one of claims 1 to 13 by means of said device, and A method comprising the step of storing in a memory module of the device a mathematical formula of the relationship between the concentration of the test substance and the change in the concentration of the intracellular marker as defined in any one of claims 1 to 13.
15. A method according to claim 14, wherein the device is initially calibrated according to the method of any one of claims 1 to 13, and constants or curve fit data derived from the regression / curve fit model are stored in the memory of the device.
16. 16. A method for determining the concentration distribution of a test substance in the extracellular phase of a sample, the method comprising the steps of measuring the total concentration of the test substance in the extracellular phase and measuring the concentration of an intracellular marker in the extracellular phase, and then calculating from the measured concentrations of the intracellular marker the contribution due to lysis of cells to the total concentration of the test substance by interpolation or extrapolation or correcting the values of the measured concentrations of the test substance, wherein a mathematical or functional relationship between the concentrations of the test substance and the concentrations of the intracellular marker has been established according to a method according to any one of claims 1 to 15.
17. 1. An apparatus for determining a test substance concentration distribution in an extracellular phase of a sample, the apparatus being configured to measure a total concentration of the test substance in the extracellular phase, measure a concentration of an intracellular marker in the extracellular phase, and then estimate, e.g. calculate, by interpolation or extrapolation, the contribution due to cellular lysis to the total concentration of the test substance from the measured concentrations of the intracellular marker based on a mathematical or functional relationship between the concentrations of the test substance and the concentrations of the intracellular marker.
18. i) the device receiving a blood cell-containing liquid sample; ii) the device measures the concentration of the analyte in the extracellular phase from the sample or part thereof comprising blood cells, and measures the concentration of an intracellular marker from the sample or part thereof comprising blood cells; iii) the device lyses a fraction of the blood cells and thereafter measures the concentration of the analyte and the concentration of the intracellular marker in the extracellular phase of a sample containing the lysed cells; iv) the apparatus optionally repeats step iii one or more times; and v) the device uses the set of measurements obtained in steps ii-iv to define the mathematical or functional relationship in a regression or curve-fitting model in the form of a function in which the concentration of the analyte is the dependent variable and the concentration of the intracellular marker is the independent variable, the relationship being between the concentration of the analyte and the change in the concentration of the intracellular marker; 20. The apparatus of claim 17, further configured to determine said mathematical or functional relationship by determining the effect of lysis of cells on a measured concentration of an analyte present in the blood cell-containing liquid sample.
19. 19. The device according to any one of claims 17 to 18, wherein the device comprises an optical measurement setup arranged for measuring the concentration of an intracellular marker in the extracellular phase and / or an electroanalytical measurement setup for measuring the total concentration of the test substance in the extracellular phase, such as an ion-selective electrode sensor, such as an ion-selective membrane electrode sensor.
20. 20. A computer program or computer program product comprising instructions for causing an apparatus according to any one of claims 17 to 19 to measure the total concentration of the test substance in the extracellular phase of a sample, to measure the concentration of an intracellular marker in the extracellular phase of a sample, and then to estimate, e.g. calculate, by interpolation or extrapolation, the contribution due to cellular lysis to the total concentration of the test substance from the measured concentrations of the intracellular marker based on a mathematical or functional relationship between the concentrations of the test substance and the concentrations of the intracellular marker.
Citation Information
Patent Citations
Analysis of hemolyzed blood specimen
JP1988050743A
Methods for Accurately Enumerating and Grading for Sensitivity Heterogeneous Cell Populations Under Cytolytic Conditions
JP1995503792A
In vitro hemolysis detection and correction of at least one blood parameter in a whole blood sample - Patent Application 20070122997
JP2021508048A
